Monte Rosa Therapeutics Inc

Research Monte Rosa Therapeutics Inc (GLUE) on Bullrun: market cap USD 1.24B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.24B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 123.67M-USD 38.60M-USD 27.50Mn/a-0.77USD 129.88MUSD 39.19MUSD 233.06M
FY2024USD 75.62M-USD 72.70MUSD 38.01Mn/a-1.03USD 224.25MUSD 42.72MUSD 222.94M
FY2023USD 0-USD 135.35M-USD 62.84Mn/an/aUSD 128.10MUSD 46.04MUSD 179.25M
FY2022n/a-USD 108.50M-USD 105.38Mn/an/aUSD 54.91MUSD 48.76MUSD 271.41M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.24Bn/an/an/a
20252025-12-31USD 1.03Bn/an/an/a
20242024-12-31USD 426.86Mn/an/an/a
20232023-12-29USD 282.96Mn/an/an/a
20222022-12-30USD 368.32Mn/an/an/a
20212021-12-31USD 950.27Mn/an/an/a

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Monte Rosa Therapeutics Inc's market cap?

Monte Rosa Therapeutics Inc's market capitalization is USD 1.24B.

What does Monte Rosa Therapeutics Inc do?

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.